- Conditions
- Hepatitis D, Chronic
- Interventions
- JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Redwood City, California • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 309
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Onychomycosis
- Interventions
- Itraconazole 100mg capsules, Itraconazole 200mg tablets, Placebo tablets
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 1,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 43 more
- Conditions
- Active Dermatomyositis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 3 more
- Conditions
- Healthy Women
- Interventions
- Placebo Film
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK189075, Bupropion, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Type 2 Diabetes Mellitus, Heart Failure
- Interventions
- Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Torrance, California • Upland, California • Miami, Florida + 7 more
- Conditions
- Multiple Sclerosis
- Interventions
- Teriflunomide, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 19
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
- Conditions
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Interventions
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
- Conditions
- Anemia, Anaemia
- Interventions
- GSK1278863, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Azusa, California • Glendale, California • Los Angeles, California + 7 more
- Conditions
- Systemic Sclerosis
- Interventions
- Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1, Nerandomilast formulation 2
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
- Conditions
- Major Depressive Disorder
- Interventions
- Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
- Conditions
- Embryo Transfer
- Interventions
- Epelsiban (GSK557296), Placebo to match GSK557296
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Perimenopausal Disorder, Stress, Emotional
- Interventions
- Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Depressive Disorder, Major
- Interventions
- GW856553, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Hoffman Estates, Illinois • Park Ridge, Illinois • New York, New York + 1 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- OATD-01, Placebo
- Drug
- Lead sponsor
- Molecure S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Kansas City, Kansas • Baltimore, Maryland + 4 more
- Conditions
- Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
- Interventions
- AZD0914, Moxifloxacin, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo to Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Orange, California • Torrance, California + 25 more
- Conditions
- Bipolar 1 Disorder
- Interventions
- ELND005, Lamotrigine, Valproic acid, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Healthy Volunteer, Opioid-use Disorder
- Interventions
- INDV-2000, Placebo, SUBOXONE® sublingual film
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
- Conditions
- Asthma
- Interventions
- GB001, Placebo
- Drug
- Lead sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more
- Conditions
- Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress Disorder
- Interventions
- BXCL501 (dexmedetomidine HCl), Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • St Louis, Missouri • Charlottesville, Virginia
- Conditions
- Multiple Myeloma
- Interventions
- Perifosine, Perifosine Placebo, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 39
- States / cities
- La Verne, California • San Francisco, California • San Pablo, California + 35 more
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
- Biological · Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more